Table 1: The main findings connected to the improvement of endothelial dysfunction from the reviewed clinical studies.

Pathological condition Drug Main effects Corresponding reference Chronic heart failure Rosuvastatin Oxidized LDL    Lipid peroxidation     Stem and progenitor cells    FMD Erbs et al. [20] Acute coronary syndrome Perindopril Apoptosis    CD34+ mobilization    VEGF    TNF-α    Bradykinin Cangiano et al. [21] Cardiac syndrome X Nebivolol FMD    High-sensitivity C-reactive protein    von Willebrand factor    Fibrinogen Kayaalti et al. [22] Hypertensive left ventricular hypertrophy Carvedilol FMD    Endothelin-1    Nitric oxide Xiaozhen et al. [23] Coronary artery disease and impaired glucose tolerance Pioglitazone FMD    TNF-α    Triglycerides    HMW adiponectin Rizza et al. [24] Hypertension and impaired glucose tolerance Telmisartan FMD    Insulin resistance    Glucose tolerance Perl et al. [25] Type 2 diabetes Gliclazide FMD    Endothelial progenitor cells Chen et al. [26] Obesity Pitavastatin FMD     Triglycerides Nagashima and Endo [27] Peripheral artery disease Telmisartan Maximum walking distance    FMD Zankl et al. [28] Behçet’s disease Atorvastatin Lisinopril FMD Inanc et al. [29] Polycystic ovary syndrome Spironolactone FMD Bajuk Studen et al. [30] Subclinical hypothyroidism L-thyroxin FMD    FT4    TSH    Total cholesterol Alibaz Oner et al. [31] Ankylosing spondylitis Infliximab FMD    Serum nitrite    Erythrocyte sedimentation rate    C-reactive protein Syngle et al. [32] Chronic hemodialysis Simvastatin FMD    Oxidized LDL    VCAM-1    8-epi-PG F2    Nitric oxide bioavailability Kishimoto et al. [33]

FMD: flow-mediated dilatation; VEGF: vascular endothelial growth factor; TNF-: tumor necrosis factor-; TSH: thyroid-stimulating hormone; VCAM-1: vascular cell adhesion molecule 1.